iconiifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Q3FY24 Review: Apollo Hospitals: Targeting break-even for 24/7 by 2HFY26

12 Feb 2024 , 02:27 PM

Recommendation: Buy; Target price: ₹7200

Apollo’s Q3 Ebitda was 2% ahead of analysts of IIFL Securities estimates led by further reduction in 24/7 Ebitda losses from Rs1.7bn to Rs1.3bn QoQ, which was partly offset by ~110bps QoQ decline in Hospitals’ Ebitda margins owing to Q3 seasonality and incremental costs from doctor hiring. While Apollo is targeting to drive 14-15% revenue growth in Hospitals by increasing occupancies to 70% (vs 65.5% currently) and improve margins in the Hospitals business by ~200bps over the next few quarters, HealthCo business will also likely grow at 22- 23% Cagr over the next few years. With Apollo achieving Ebitda break-even for HealthCo in Q3FY24, mgmt has now guided for break-even for 24/7 in the next 6-8 quarters and analysts of IIFL Securities estimates currently assume the same in Q4FY26. Analysts of IIFL Securities marginally upgrade FY24-26 Ebitda by 0-2% led by higher margins and expect Apollo to clock 29% Ebitda Cagr (18% ex-24/7) over FY24-27. Apollo & KIMS are their preferred-picks. TP of ₹7,200 implies 12% upside. 

Analysts of IIFL Securities expect Hospitals business to clock 15% Cagr over FY24-27 led by improving occupancies and ARPOB growth: 

Hospital business growth of 12% YoY in Q3 was driven by 6% IP volume growth and 10% ARPOB growth. Insurance business witnessed 16% growth in Q3 and accounted for 43% of IP revenues. Mgmt expects 200bps improvement in Hospital business Ebitda margins over the next few quarters, driven by focus on IP volume growth and improving occupancies, improving specialty mix from onco/renal/cardiac, and operating leverage from recent doctor additions. Apollo’s capacity expansion plans also remain on track with ~2,000 beds to be added at a capex outlay of Rs30bn over the next 4 years. 

Apollo 24/7 on track to achieve break-even in next 6-8 quarters: 

Mgmt has done a remarkable job in reducing 24/7 losses for the 3rd straight quarter from Rs1.9bn in Q4FY23 to Rs1.3bn in Q3FY24. While HealthCo generated positive Ebitda of Rs20m in Q3FY24, mgmt now expects to achieve Ebitda break-even for 24/7 over the next 6-8 quarters driven by digital therapeutics, recently launched insurance distribution business, and app monetization efforts. GMV for 24/7 is likely to grow 60-70% in FY25 (analysts of IIFL Securities have factored-in 55% growth) following ~70% growth in FY24. 

Analysts of IIFL Securities TP of ₹7,200 for Apollo is based on ~26/23x FY26 EV/Ebitda for the Hospitals/Offline Pharmacy business and 0.75x GMV for 24/7, which implies target market cap of USD10bn for the Hospitals business and USD2.5bn for the HealthCo entity.

Related Tags

  • Apollo Hospitals
sidebar mobile


19 Feb 2024   |   09:29 AM
Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.